Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
DECOY THERAPEUTICS INC (DCOY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.12-1.75%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for DCOY yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise capital through private placement to fund operations | The company raised capital through a private placement in June 2026. | Intact | Private placement fails to close or raises significantly less capital than planned | Private placement closed on June 29, 2026 vs target June 29, 2026 8-K filings confirm the private placement closed on June 29, 2026, as planned, with subsequent warrant exercises in September. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business rather than an established compounder. Its long-term thesis is in a watch state, with recent financial performance below its industry cohort and no fresh break in the thesis.
The valuation evidence describes DCOY as cheap versus peers, with no peer premium. The priced-in evidence says weak execution quality is reflected, but does not show the full combination of expensive valuation, weak execution, and turbulence being priced in.
Near term, earnings-miss risk is elevated, while recent financial performance is rated neutral. Operating losses and negative cash flow have persisted, and the company has continued to raise capital through private placements and warrant transactions. Regaining Nasdaq compliance was progress, but a one-year monitoring period remains.
Over the next few quarters, the thesis hinges on whether DCOY can reduce operating losses and cash needs while managing further financing. A weakening jobs report could increase pressure on cyclical names, while continued strength from Healthcare bellwethers could support the sector backdrop; misses or lower guidance from those companies could weaken that support.
For the next 1 to 3 years, the long-term thesis is speculative and depends on better financial execution, with sector momentum offering a possible tailwind but not resolving the business’s persistent losses. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Despite losses, net income reached positive $16.06M in 2025-Q4, showing potential progress. |
| Broken |
| Operating losses worsen beyond negative $9M or net income remains negative through FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Address Nasdaq listing compliance on minimum bid price | A supporting condition in DECOY THERAPEUTICS INC's published investment case. The stated target is Compliance with Nasdaq listing rule 5550(a)(2) by end of 2026. | Under Pressure | Failure to regain compliance results in delisting or trading suspension | Price $1.12 vs $1.00 min No compliance news; price action shows severe decline to $1.12, threatening Nasdaq listing status. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-19.32 → $-8.28 · observed estimates
FY2027 revenue: comparable history unavailable.
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-19.32 | Unavailable | 1 / 0 |
| 2026-07-25 | $-19.32 | Unavailable | 1 / 0 |
| 2026-07-26 | $-19.32 | Unavailable | 1 / 0 |
| 2026-07-27 | $-19.32 | Unavailable | 1 / 0 |
| 2026-07-28 | $-19.32 | Unavailable | 1 / 0 |
| 2026-07-29 | $-19.32 | Unavailable | 1 / 0 |
| 2026-07-30 | $-19.32 | Unavailable | 1 / 0 |
| 2026-07-31 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-01 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-02 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-03 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-04 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-05 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-06 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-07 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-08 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-09 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-10 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-11 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-12 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-13 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-14 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-15 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-16 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-17 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-18 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-19 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-20 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-21 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-22 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-23 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-24 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-25 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-26 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-27 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-28 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-29 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-30 | $-19.32 | Unavailable | 1 / 0 |
| 2026-08-31 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-01 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-02 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-03 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-04 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-05 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-06 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-07 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-08 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-09 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-10 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-11 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-12 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-13 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-14 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-15 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-16 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-17 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-18 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-19 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-20 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-21 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-22 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-23 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-24 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-25 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-26 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-27 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-28 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-29 | $-19.32 | Unavailable | 1 / 0 |
| 2026-09-30 | $-19.32 | Unavailable | 1 / 0 |
| 2026-10-01 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-02 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-03 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-04 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-05 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-06 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-07 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-08 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-09 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-10 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-11 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-12 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-13 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-14 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-15 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-16 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-17 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-18 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-19 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-20 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-21 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-22 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-23 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-24 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-25 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-26 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-27 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-28 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-29 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-30 | $-8.28 | Unavailable | 1 / 0 |
| 2026-10-31 | $-8.28 | Unavailable | 1 / 0 |
| 2026-11-01 | $-8.28 | Unavailable | 1 / 0 |
| 2026-11-02 | $-8.28 | Unavailable | 1 / 0 |
| 2026-11-03 | $-8.28 | Unavailable | 1 / 0 |
| 2026-11-04 | $-8.28 | Unavailable | 1 / 0 |
| 2026-11-05 | $-8.28 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.